ProCE Banner Activity

Expert Thoughts on Navigating Complexities in HER2+ MBC Sequencing

Clinical Thought

In this commentary, expert faculty address frequently asked questions and share their perspectives on managing complexities in treatment sequencing, including the presence of brain metastases in the second-line setting and beyond in the rapidly evolving therapeutic area of HER2+ metastatic breast cancer.

Released: May 07, 2025

Expiration: November 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Ian Krop, MD, PhD: consultant/advisor/speaker: ALX Oncology, AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech/Roche, Novartis, Ottimo, Pfizer, Seagen.

Sarah L. Sammons, MD: researcher: Daiichi Sankyo, Relay Therapeutics, Seagen, Sermonix; consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Incyclix, Lilly, Novartis, Pfizer, Seagen, Sermonix.